Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $86,839.39 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 11,119 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the sale, the insider now owns 193,444 shares of the company’s stock, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Donald Notman also recently made the following trade(s):

• On Friday, January 31st, Donald Notman sold 6,301 shares of Ocular Therapeutix stock. The stock was sold at an average price of $7.84, for a total value of $49,399.84.

Ocular Therapeutix Price Performance

OCUL opened at $7.64 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The company’s 50 day moving average is $8.57 and its 200-day moving average is $9.01. Ocular Therapeutix, Inc. has a 1-year low of $4.06 and a 1-year high of $11.77.

Institutional Trading of Ocular Therapeutix

Hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 1,015 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in Ocular Therapeutix during the 3rd quarter worth $70,000. Algert Global LLC acquired a new position in Ocular Therapeutix in the 2nd quarter worth about $69,000. Palumbo Wealth Management LLC acquired a new position in Ocular Therapeutix in the 4th quarter worth about $100,000. Finally, Diversified Trust Co bought a new position in Ocular Therapeutix in the third quarter valued at about $106,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Analyst Upgrades and Downgrades

OCUL has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank began coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.